In last trading session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) saw 2.07 million shares changing hands with its beta currently measuring -0.62. Company’s recent per share price level of $2.13 trading at $0.14 or 7.04% at ring of the bell on the day assigns it a market valuation of $145.01M. That closing price of AMLX’s stock is at a discount of -949.77% from its 52-week high price of $22.36 and is indicating a premium of 25.82% from its 52-week low price of $1.58. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.23 million shares which gives us an average trading volume of 1.69 million if we extend that period to 3-months.

For Amylyx Pharmaceuticals Inc (AMLX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.71. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.68 in the current quarter.

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information

Upright in the green during last session for gaining 7.04%, in the last five days AMLX remained trading in the green while hitting it’s week-highest on Wednesday, 08/14/24 when the stock touched $2.13 price level, adding 0.47% to its value on the day. Amylyx Pharmaceuticals Inc’s shares saw a change of -85.53% in year-to-date performance and have moved 13.30% in past 5-day. Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) showed a performance of -9.75% in past 30-days. Number of shares sold short was 1.86 million shares which calculate 0.96 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 29.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -40.85% in reaching the projected high whereas dropping to the targeted low would mean a loss of -40.85% for stock’s current value.

Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts

Statistics highlight that Amylyx Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -85.76% of value to its shares in past 6 months, showing an annual growth rate of -650.00% while that of industry is 17.20. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -76.90% from the last financial year’s standing.

Company posted 102.69M and 108.45M of sales in current and next quarters respectively a year earlier.

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders

Insiders are in possession of 14.21% of company’s total shares while institution are holding 83.88 percent of that, with stock having share float percentage of 97.77%. Investors also watch the number of corporate investors in a company very closely, which is 83.88% institutions for Amylyx Pharmaceuticals Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at AMLX for having 5.35 million shares of worth $15.19 million. And as of 2024-03-31, it was holding 7.9332 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 4.47 million shares on 2024-03-31. The number of shares represents firm’s hold over 6.6376 of outstanding shares, having a total worth of $12.71 million.